Ludwig San Diego
AT EVERY STEP OF THE RESEARCH PROCESS FROM THE LAB TO THE CLINIC, WE ARE PURSUING INNOVATIVE WAYS TO PREVENT AND CONTROL CANCER.
Stephen Hodi, an investigator at Ludwig Harvard, reports that 34 percent of patients with advanced melanoma who were treated the immunotherapy nivolumab alone were still alive five years later.
Congratulations to Ludwig Johns Hopkins Co-Director Kenneth Kinzler and Ludwig Harvard scientist Myles Brown for this well-deserved recognition of their significant achievements in original research.
Ludwig and CRI are partnering with MedImmune and VentiRx to test a combination immunotherapy for metastatic ovarian cancer, a disease for which patients today have few treatment options.